MENLO PARK, Calif.,
Jan. 23, 2017 /PRNewswire/
-- The Board of Directors of BioPharmX Corporation (NYSE MKT:
BPMX), a specialty pharmaceutical company focusing on dermatology,
today announced the appointment of Charles "Greg" Vontz as an
independent director, effective as of Jan. 17. Vontz's
appointment expands the board to four directors, three of whom are
independent.
"Greg brings 30 years of experience within the dermatology,
biotechnology and pharmaceutical industries and will provide a
valuable industry perspective to our board of directors," said
Anja Krammer, president. "We
are fortunate to have him join our board and look forward to
benefitting from his expertise and counsel."
Vontz most recently served as president and CEO of Topica
Pharmaceuticals, which developed luliconazole for fungal infections
of the skin, a product acquired by Medicis Pharmaceutical
Corporation. Earlier, he was president and chief operating officer
of Connetics Corporation, a public specialty pharmaceutical
company, focusing on dermatology. Connetics was acquired by
Stiefel Pharmaceuticals in late 2006.
Before joining Connetics, Vontz spent 12 years at Genentech in
various senior marketing and product development roles. He
got his start in the pharmaceutical industry with Merck, Sharp and
Dohme where he worked from 1985-1987 in sales and sales
management.
"I am pleased to join BioPharmX's board at this
important time in the company's evolution," said Greg Vontz.
"I understand the dermatology community's great need for topical
drug treatments and BioPharmX is well positioned with its
innovative new-product technology in topical drug delivery. I look
forward to working with the management team to achieve the
company's goals."
Vontz is also a member of the board of directors for SinuSys
Corporation. He is a graduate of the University of Florida and received a Masters in
Business Administration from the Haas School of Business at the
University of California at
Berkeley.
About BioPharmX® Corporation
BioPharmX Corporation (NYSE MKT: BPMX) is a Silicon Valley-based
specialty pharmaceutical company, which seeks to provide products
through proprietary platform technologies for prescription,
over-the-counter (OTC), and supplement applications in the health
and wellness markets, including dermatology and women's health.
BioPharmX and Violet are registered trademarks of BioPharmX, Inc.
To learn more about BioPharmX, visit www.BioPharmX.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/specialty-pharma-industry-veteran-charles-gregory-vontz-joins-biopharmx-board-of-directors-300394487.html
SOURCE BioPharmX Corporation